The labelling puts it in direct contention with Pfizer's ... include pursuing regulatory approvals outside the US, starting with Europe – where it has already filed the drug, with a decision ...

Biotechnology has emerged as a driving force in transforming healthcare. Over the past few decades, the integration of biology with advanced technology has led to significant breakthroughs. These ...

As New Zealand eyes a free trade agreement with India, experts say the next frontier could be pharmaceutical imports - ...

After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial. Tanezumab is a nerve growth factor (NGF ...